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Abstract 
In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients 
were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase 
of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were as-
sessed by in vitro assay and delayed-type hypersensitivity skin testing. 
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In-vivo targeting of dendritic cells (DC) has been 
shown  to  confer  strong  and  protective  cytotoxic  T 
lymphocyte (CTL)–based immunity in tumor murine 
models. Our group has recently demonstrated in pre-
clinical models1 that the infusion of genetically modi-
fied lymphocytes (GMLs) expressing the self/tumor 
antigen  TRP-2  is  able  to  elicit  functional 
TRP-2–specific  effectors  with  antitumor  activity  by 
targeting DCs in vivo. The mechanism responsible for 
the  induction  of  such  an  immune  response  is  the 
cross-presentation  of  the  antigen  mediated  by  the 
CD11c+CD8α+  DC  subset.  Furthermore,  we  demon-
strated in vivo and in vitro that DCs had undergone 
activation upon phagocytosis of genetically modified 
lymphocytes,  a  process  mediated  by  a  cell-to-cell 
contact mechanism independent of CD40 triggering. 
Targeting and activation of secondary lymphoid or-
gan–resident  DCs  endowed  antigen-specific  T  cells 
with  full  effector  functions,  which  ultimately  in-
creased tumor growth control and animal survival in 
a therapeutic tumor setting. This original strategy was 
exploited for active immunotherapy of patients with 
advanced melanoma, a tumor with known suscepti-
bility  to  immune  control2.  Autologous  lymphocytes 
collected by apheresis were transduced with retrovi-
ral  supernatant  (Sup  PG13LM3TN  #21,  MolMed 
S.p.A.)  containing  LM3TN  vector,  a  construct  that 
expresses the genes MAGE-A3 and the HSV-TKneo 
fusion  protein  (TN)  (i.e.  M3TN  vector). 
Transgene-expressing  cells  were  G418  selected  and 
expanded in GMP conditions, and subsequently fro-
zen.  We  have  already  reported3  vaccine-  and  tu-
mor-specific immune responses of 10 melanoma pa-
tients treated with autologous GMLs expressing the 
cancer germline gene MAGE-A3. Three of 10 patients 
treated with MAGE-A3–GML showed an increase of 
circulating  anti–MAGE-A3  T  cells,  and  developed 
skin delayed-type hypersensitivity to MAGE-A3. In-
terestingly,  in  2  of  these  patients,  with  progressive 
and  measurable  tumors  at  study  entry,  an-
ti–MAGE-A3  T  cells  were  detected  not  only  in  the 
blood but also within tumors resected after vaccina-
tion.  These  results  suggest  that  the  infusion  of 
MAGE-A3–GML elicits antitumor T cells, which are 
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capable of trafficking to inflamed tissues and of infil-
trating tumors. We are now analyzing the clinical re-
sults of this strategy on a larger group of patients to 
evaluate  its  clinical  efficacy.  In  this  bi-institutional 
study,  twenty-three  stage  IIIC-IV  MAGE-A3+  mela-
noma patients were vaccinated with M3TK-GML bi-
weekly at three dose levels, with a subsequent phase 
of  vaccinations  at  the  maximum  dose  level.  An-
ti-MAGE-A3 and anti-TK T cells were assessed by in 
vitro  assay  and  delayed-type  hypersensitivity  skin 
testing.  Patients  with  measurable  disease  (19)  were 
evaluated for objective clinical response by Response 
Evaluation Criteria in Solid Tumors. All patients were 
pretreated with surgery, and the majority with chem-
otherapy and/or immunotherapy. Eight patients had 
skin/subcutaneous disease only, and the remainder 
had visceral disease. LDH levels were elevated in 8 
(36%)  of  the  patients.  Clinical  responses,  progres-
sion-free  survival  and  overall  survival  will  be  as-
sessed  and  correlated  with  the  generation  of  anti-
tumor immune response. 
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